RB1 and neoplasm: Palbociclib/PD-0332991 is a CKI targeting CDK4/6 that is FDA-approved for breast cancer and has been demonstrated to effectively decrease phosphorylation of RB, causing a potent anti-proliferative effect in a variety of adult tumor cells [149].